Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
Organon Canada and Henlius launched BILDYOS and TUZEMTY, biosimilars to PROLIA and XGEVA, now available in Canada for osteoporosis and bone events associated with cancer. The launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas, leveraging products with more than nine years of market experience.
Key figures
- Portfolio size canada
- 8
- Market experience years
- 9
- Therapeutic areas canada
- 5
- Osteoporosis patients canada
- 2.3 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.